Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy.

IF 6.7
Oncolytic Virotherapy Pub Date : 2015-11-20 eCollection Date: 2015-01-01 DOI:10.2147/OV.S66081
Hiroshi Nakashima, Tran Nguyen, Ennio Antonio Chiocca
{"title":"Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy.","authors":"Hiroshi Nakashima, Tran Nguyen, Ennio Antonio Chiocca","doi":"10.2147/OV.S66081","DOIUrl":null,"url":null,"abstract":"<p><p>Histone deacetylase (HDAC) enzymes play a critical role in the epigenetic regulation of cellular functions and signaling pathways in many cancers. HDAC inhibitors (HDACi) have been validated for single use or in combination with other drugs in oncologic therapeutics. An even more novel combination therapy with HDACi is to use them with an oncolytic virus. HDACi may lead to an amplification of tumor-specific lytic effects by facilitating increased cycles of viral replication, but there may also be direct anticancer effects of the drug by itself. Here, we review the molecular mechanisms of anti-cancer effects of the combination of oncolytic viruses with HDACi. </p>","PeriodicalId":19491,"journal":{"name":"Oncolytic Virotherapy","volume":"4 ","pages":"183-91"},"PeriodicalIF":6.7000,"publicationDate":"2015-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/60/95/ov-4-183.PMC4918398.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncolytic Virotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OV.S66081","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Histone deacetylase (HDAC) enzymes play a critical role in the epigenetic regulation of cellular functions and signaling pathways in many cancers. HDAC inhibitors (HDACi) have been validated for single use or in combination with other drugs in oncologic therapeutics. An even more novel combination therapy with HDACi is to use them with an oncolytic virus. HDACi may lead to an amplification of tumor-specific lytic effects by facilitating increased cycles of viral replication, but there may also be direct anticancer effects of the drug by itself. Here, we review the molecular mechanisms of anti-cancer effects of the combination of oncolytic viruses with HDACi.

将 HDAC 抑制剂与溶瘤病毒疗法结合用于癌症治疗。
组蛋白去乙酰化酶(HDAC)在许多癌症的细胞功能和信号通路的表观遗传调控中发挥着关键作用。HDAC 抑制剂(HDACi)已被证实可单独使用或与其他药物联合使用,用于肿瘤治疗。一种更为新颖的 HDACi 联合疗法是将其与溶瘤病毒一起使用。HDACi可能会通过促进病毒复制周期的增加而放大肿瘤特异性溶解效应,但药物本身也可能具有直接抗癌作用。在此,我们回顾了溶瘤病毒与HDACi结合的抗癌作用的分子机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信